Specialty Pharmacy

Top five articles of the week from Specialty Pharmacy Times.

Top news of the day from across the health care landscape.

2D material nanopores are able to map DNA methylations.

Pharmacy benefit manager reduced prescription drug spending among injured workers.

Hypermutated HIV suppresses immune response.

Glecaprevir/pibrentasvir achieved 99% sustained virologic response rate in patients with chronic HCV with compensated cirrhosis.

Findings could help improve treatment efficacy for patients with ALL.

Marc O'Connor, COO and Chief Strategy Officer at Curant Health, discusses how pharmacies can help patients manage high drug costs.

Combination therapy may lead to more effective cancer treatments.

Top news of the day from across the health care landscape.

Multiple myeloma survivor seeks to empower patients by illustrating the value of human life.

Decline in cancer incidence rates most likely driven by modern antiretroviral therapies.

MicroRNA 506 triggers autophagy-related cell death in pancreatic cancer cells.

Novel test can detect circulating tumor DNA to determine if a patient has metastatic melanoma.

Hyper-sensitive test detects tumors earlier than current technology.

Top news of the day from across the health care landscape.

Patient engagement and involvement found to be crucial to in effective rheumatoid arthritis treatment.

First of its kind pharmacy aligns a pharmacy benefit manager and a retail giant.

The final part of a 4-part interview with an infectious disease expert examines the furture treatment landscape and caring for an aging HIV population.

Protein determines whether breast cancer cells become resistant to tamoxifen.

Relapsing-remitting multiple sclerosis treatment found to trigger programmed cell death.

Novel treatment brings oxygen to hypoxic brain tumors.

Top news of the day from across the health care landscape.

Kevin James, RPh, MBA, vice president of Payer Strategy at US Bioservices, discusses optimal support for distribution of specialty therapies.

Ranibizumab injection (Lucentis) 0.3-mg approved for the treatment of all forms of diabetic retinopathy.

Atezolizumab is the first and only approved anti-PDL1 cancer immunotherapy.

A data-rich specialty industry can improve treatment strategies.

The third of a 4-part interview with an infectious disease expert discusses the impact of specialty drugs and the potential loss of funding to HIV treatment programs.